rhIGF-I/rhIGFBP-3, SomatoKine, Found to Delay the Onset of Type
2003-12-02 14:05 (New York)
I Diabetes
Health/Medical Writers / Business Editors
BIOWIRE2K
RICHMOND, Va.--(BUSINESS WIRE)--Dec. 2, 2003
IGF-I Complex Found More Efficient Than Free IGF-I
In Preventing Beta Cell Destruction
Insmed's (NASDAQ: INSM) rhIGF-I/rhIGFBP-3 (SomatoKine(R)), has
been found by an independent research team to protect from the onset
of type 1 diabetes in non-obese diabetic mice. The independent
research team found that both free IGF-I and rhIGF-I/rhIGFBP-3 complex
were effective in reducing the severity of insulitis, beta cell
destruction and delayed the onset of type 1 diabetes, however,
Insmed's rhIGF-I/rhIGFBP-3 complex was a significantly more effective
treatment in the prevention of type 1 diabetes.
The study, "IGF-I/IGF-Binding Protein-3 (IGFBP-3) Complex:
Therapeutic Efficacy and Mechanism of Protection Against Type 1
Diabetes," was conducted by researchers at The Robarts Research
Institute and the department of Microbiology and Immunology,
University of Western Ontario and published by Endocrinology in a
rapid electronic publication, which makes research papers accessible
to readers up to 12 weeks prior to printing. The study was supported
by grants from the Canadian Institutes of Health Research and the
Juvenile Diabetes Research Foundation and led by T.L. Delovitch, the
Sheldon H. Weinstein Scientist in Diabetes at the University of
Western Ontario.
Please access the abstract of this paper through the Insmed
corporate website, www.insmed.com.
More on rhIGF-I/rhIGFBP-3 (SomatoKine(R))
Insmed's rhIGF-I/rhIGFBP-3 is a proprietary delivery composition
of insulin-like growth factor-I (IGF-I). The novel compound is
administered as a once-daily subcutaneous injection, which can restore
IGF levels to physiological relevant levels. In diabetic subjects,
administration of rhIGF-I/rhIGFBP-3 demonstrated a significant
improvement in blood sugar control and a significant reduction in
daily insulin use. Following severe burn injury, in both children and
adults, administration of rhIGF-I/rhIGFBP-3 demonstrated a significant
improvement in muscle protein synthesis and a significant reduction in
the inflammatory response associated with the trauma. In recovery from
hip fractures, administration of rhIGF-I/rhIGFBP-3 has demonstrated a
significant improvement in functional recovery and bone mineral
density. rhIGF-I/rhIGFBP-3 is currently in a pivotal Phase III
clinical trial for the treatment of Growth Hormone Insensitivity
Syndrome (GHIS), a severe growth disorder.
About Insmed Incorporated
Insmed is a biopharmaceutical company focused on the discovery and
development of drug candidates for the treatment of metabolic diseases
and endocrine disorders with unmet medical needs. For more
information, please visit www.insmed.com. |
